Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Baxter Acquires AesRx, LLC

Published: Thursday, July 10, 2014
Last Updated: Thursday, July 10, 2014
Bookmark and Share
Program carries potential to address significant unmet patient need.

Baxter International Inc. has announced the acquisition of AesRx, LLC, a private U.S. biopharmaceutical company focused on orphan drug targets, including the development and commercialization of Aes-103, an investigational prophylactic treatment for sickle cell disease (SCD).

Aes-103 is a first-in-class, oral, small molecule compound (5-hydroxymethylfurfural). Early studies indicate the compound may work by binding to hemoglobin and increasing oxygen affinity and stabilization, thereby reducing the sickling of red blood cells which, in turn, may reduce sickling-related outcomes such as vaso-occlusive crisis, pain, severe anemia, and fatigue. Aes-103 has received Orphan designation from the FDA and is eligible for Orphan designation in Europe.

The Aes-103 program is currently in a Phase 2 clinical trial as part of an ongoing collaboration with the NIH's National Center for Advancing Translational Sciences (NCATS) through its Therapeutics for Rare and Neglected Diseases (TRND) program. Data has previously been presented from an escalating dose Phase I/2a safety study involving administration of a single dose among stable SCD patients.

The compound, originally patented by Virginia Commonwealth University, was developed by a team from the VCU Institute for Structural Biology and Drug Discovery, an interdisciplinary research center spanning the university's Schools of Medicine and Pharmacy.

"Sickle cell disease was the first disease to ever have its molecular cause discovered, and now a potential treatment based on that discovery has at last been developed," said NCATS Director Christopher P. Austin, M.D. "This success validates the NCATS model, which is based on a novel collaborative approach that de-risks intervention development programs to enable private-sector investment. We look forward to applying this model to the thousands of rare diseases that are currently untreatable, so that we realize the NCATS mission of getting more treatments to more patients more quickly."

Baxter made an initial payment to acquire the company and may make additional future payments based on specified development, regulatory and commercial milestones. The specific terms of the agreement were not disclosed.

"With this acquisition, we gain a compound that has the potential to address an extremely high unmet clinical need in a community with inadequate treatment options and no recent major clinical developments," said Ludwig Hantson, Ph.D., president of Baxter BioScience. "This program is complementary to our established experience in hemophilia and supports our goals to raise the bar for care of patients with a range of blood-related disorders."

"By becoming a part of Baxter's organization, we believe this will provide Aes-103 the needed resources and expertise to complete a robust development and commercialization program," commented Stephen Seiler, AesRx's Founder and former Chief Executive Officer. "Baxter has a demonstrated track record in the treatment of hematological orphan diseases and is an ideal company to take this important program forward."


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,600+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Baxter to Acquire Oncaspar® Portfolio for Leukemia
New portfolio strengthens leadership in rare and orphan diseases for Baxter, expected to become Baxalta by mid-2015.
Saturday, May 16, 2015
Baxter to Divest Vero Cell Vaccines Platform to Nanotherapeutics
Agreement includes all assets related to the platform, including vaccines for H5N1, H1N1 and seasonal influenza.
Thursday, December 18, 2014
Baxter to Form New Global Innovation and R&D Center
Company plans to form new center near Boston for its biopharmaceuticals business.
Friday, October 10, 2014
Baxter and Merrimack Enter into Exclusive Ex-U.S. Licensing Agreement
Baxter gains exclusive commercialization rights for all potential indications of MM-398 in all other geographies outside Taiwan.
Friday, September 26, 2014
Baxter Announces Topline Results of Phase III Study of Immunoglobulin for Alzheimer's
Phase III clinical study of immunoglobulin (IG) did not meet its co-primary endpoints of reducing cognitive decline and preserving functional abilities in patients with mild to moderate Alzheimer’s disease.
Thursday, May 09, 2013
Baxter Announces Long-Term Partnership in Brazil
Company to expand access to recombinant FVIII hemophilia treatment.
Friday, November 09, 2012
Baxter Announces FDA Approval of ADVATE 4000 IU Dosage Strength
New size expands convenience options for hemophilia A patients.
Wednesday, July 18, 2012
Scientific News
What Makes a Good Scientist?
It’s the journey, not just the destination that counts as a scientist when conducting research.
Investigational Malaria Vaccine Protects Healthy U.S. Adults
Researchers at NIH have found that the malaria vaccine protected a small number of healthy, malaria-naïve adults in the U.S. from infection for more than one year after immunization.
AACR 2016: Cancer Immunotherapy and Beyond
At this year's meeting there was a palpable buzz around subjects ranging from microbiomics to the tumor microenvironment and cancer vaccines, big data to in vitro and in vivo modeling and drug delivery (to name just a few).
New Database for Sharing MS Clinical Trial Data
A new database containing nearly 2500 patient records from the placebo arms of nine multiple sclerosis (MS) clinical trials is now available for research by qualified investigators.
Study Finds Factors That May Influence Influenza Vaccine Effectiveness
Researchers at NIH have suggested that the long-held approach to predicting seasonal influenza vaccine effectiveness may need to be revisited.
BMS’s Opdivo Clinical Trial Shows Promise
Safety profile of the combination regimen from CheckMate -069 was consistent with previously reported studies and adverse events were managed using established safety algorithms.
Treatment of Common Prostate Cancer
Researchers at UTSW have found that the prostate cancer treatments suppress immune response and may promote relapse.
Cancer Drug Could Treat Blood Vessel Deformities
A drug currently being trialled in cancer patients could also be used to treat an often incurable condition that can cause painful blood vessel overgrowths inside the skin.
Structure of Crucial Enzyme Identified
Researchers at UTSW have determined the atomic structure of an enzyme that plays an essential role in cell division and better treatment of cancer.
New Immunotherapy Trial for Type 1 Diabetes
The search for a treatment for Type 1 diabetes (T1D) - which affects over 400,000 people in the UK – will be stepped up with the start of a new phase one clinical trial at Guy’s Hospital in London.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,600+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!